Suspended

Comparing Initial Glaucoma Treatment: Medication vs Surgery

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Data Collection

Who is being recruted

Eye Diseases+1

+ Glaucoma

+ Glaucoma, Open-Angle

From 25 to 75 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 3
Interventional
Study Start: October 1993
See protocol details

Summary

Principal SponsorNational Eye Institute (NEI)
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: October 1, 1993

Actual date on which the first participant was enrolled.

The Collaborative Initial Glaucoma Treatment Study (CIGTS) is a research project focused on finding the best way to manage newly diagnosed open-angle glaucoma (OAG). Glaucoma is a condition that damages the eye's optic nerve, often due to high pressure inside the eye. Traditionally, eye drops are used to treat this condition. However, recent studies suggest that immediate surgery might be more effective. This study is important because it aims to improve the care and quality of life for people with OAG by determining which treatment approach works best. In this study, participants with newly diagnosed OAG are assigned to one of two treatment groups. One group receives a series of eye drop medications, starting with a single agent, usually a beta blocker. If the eye drops don't control the pressure inside the eye or if the patient's vision worsens, additional treatments are used, including argon laser trabeculoplasty and, if necessary, surgery. The other group undergoes immediate surgery, called trabeculectomy. If this surgery fails, they receive argon laser trabeculectomy, followed by medication if needed. Patients are assigned to these groups by chance, and if both eyes are eligible for treatment, they receive the same treatment. Throughout the study, participants visit the Clinical Centers for regular check-ups to evaluate their vision, eye pressure, and overall eye health. They also complete interviews over the phone to assess their health-related quality of life.

Official TitleCollaborative Initial Glaucoma Treatment Study (CIGTS)
Principal SponsorNational Eye Institute (NEI)
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 25 to 75 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Eye DiseasesGlaucomaGlaucoma, Open-AngleOcular Hypertension

Criteria

Patients must be at least 25 years old with an intraocular pressure of 20 mm Hg or greater and evidence of optic nerve damage and/or visual field loss in one or both eyes. The ocular findings must exclude causes of glaucoma other than primary open-angle glaucoma, pigmentary glaucoma, or pseudoexfoliation glaucoma.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has no location dataSave this study to your profile to know when the location data is available.
SuspendedNo study centers